{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:36:13Z","timestamp":1772793373886,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ygyno.2018.08.012","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T06:02:56Z","timestamp":1535090576000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial"],"prefix":"10.1016","volume":"151","author":[{"given":"Jee Suk","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Wun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Kyu","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.08.012_bb0005","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study","volume":"35","author":"Pignata","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0010","series-title":"NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer, Version 5","author":"Fort Washington","year":"2017"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bpobgyn.2016.11.005","article-title":"Role of radiation therapy","volume":"41","author":"Eifel","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/gyno.1993.1302","article-title":"Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer","volume":"51","author":"Davidson","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1525-1438.2002.01096.x","article-title":"Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy","volume":"12","author":"Fujiwara","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ygyno.2004.11.008","article-title":"Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer","volume":"96","author":"Albuquerque","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jrr\/rrs108","article-title":"Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy","volume":"54","author":"Yahara","year":"2013","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ygyno.2013.04.469","article-title":"Involved-field radiation therapy for locoregionally recurrent ovarian cancer","volume":"130","author":"Brown","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000357269","article-title":"Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer","volume":"86","author":"Machida","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3857\/roj.2017.00213","article-title":"Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment","volume":"35","author":"Choi","year":"2017","journal-title":"Radiat. Oncol. J."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/IGC.0000000000000653","article-title":"Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer","volume":"26","author":"Albuquerque","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2018.08.012_bb0075","first-page":"1465","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/COC.0000000000000310","article-title":"Secondary surgery versus chemotherapy for recurrent ovarian cancer","volume":"41","author":"Bickell","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2016.02.005","article-title":"Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy","volume":"141","author":"Chundury","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0090","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fonc.2017.00177","article-title":"Radiation treatment in women with ovarian cancer: past, present, and future","volume":"7","author":"Fields","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3802\/jgo.2013.24.2.146","article-title":"Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy","volume":"24","author":"Chang","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0110","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.08.012_bb0115","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.08.012_bb0120","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(17)32418-2","article-title":"PARP inhibitors for targeted treatment in ovarian cancer","volume":"390","author":"Dizon","year":"2017","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:14:39Z","timestamp":1540487679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818311296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0090825818311296"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}